Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lantern PharmaLTRN -4.70%34 3-Year ROIIC % is 608.06 as of Dec. 2025, which is at its 10-year median of 608.06. GuruFocus rates LTRN with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 1,322 Biotechnology companies, Lantern Pharma ranks better than 91.53% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Lantern Pharma's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 608.06%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Lantern Pharma's 3-Year ROIIC % or its related term are showing as below:
LTRN's 3-Year ROIIC % is ranked better than 91.53% of 1322
companies
in the Biotechnology industry
Industry Median: -4.9
vs LTRN: 608.06
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Lantern Pharma 3-Year ROIIC % Related Terms
Lantern Pharma 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Lantern Pharma's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTRN vs PDSB, AURX, TIL: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Lantern Pharma's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lantern Pharma 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lantern Pharma's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Lantern Pharma's 3-Year ROIIC % falls into.
Lantern Pharma's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -17.978 (Dec. 2025) - -14.433 (Dec. 2022) )
/
( 0.312 (Dec. 2025) - 0.895 (Dec. 2022) )
=
-3.545
/
-0.583
=
608.06%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Lantern Pharma (LTRN) has a 3-Year ROIIC % of 608.06 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Lantern Pharma and its competitors. This is near median its historical median of 608.06. According to the industry distribution chart, Lantern Pharma ranks #112 out of 1322 companies in the Biotechnology industry, placing it in the top 8.5%.
Is Lantern Pharma's 3-Year ROIIC % too high?
Lantern Pharma's current 3-Year ROIIC % of 608.06 is near median its 10-year median of 608.06. Based on the distribution chart, Lantern Pharma ranks #112 out of 1322 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Lantern Pharma has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Lantern Pharma's 3-Year ROIIC % compare to PDSB and AURX?
According to the Biotechnology industry distribution chart, Lantern Pharma ranks #112 out of 1322 companies for 3-Year ROIIC %. This places Lantern Pharma in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Lantern Pharma and its competitors. Lantern Pharma's current 3-Year ROIIC % is 608.06, which is near median its own 10-year median of 608.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lantern Pharma stock overvalued right now?
Lantern Pharma (LTRN) has a current 3-Year ROIIC % of 608.06. The current 3-Year ROIIC % is 608.06, which is near median its 10-year median of 608.06. Lantern Pharma's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Lantern Pharma (LTRN), the current 3-Year ROIIC % is 608.06 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
34GF Score
Get the complete analysis for LTRN
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTRN has been successfully added to your 
